Comment on: Greenbaum et al. Through the Fog: Recent Clinical Trials to Preserve β-Cell Function in Type 1 Diabetes. Diabetes 2012;61:1323–1330
- From the Department of Nutrition, Metabolic Diseases, and Endocrinology, Hospital “La Timone,” Aix-Marseille University, Marseille, France
- Corresponding author: Bernard Vialettes, .
The interesting article by Greenbaum et al. (1) attempts to trace future pathways toward curative treatments of type 1 diabetes by analyzing the lessons from the previously published trials, particularly those performed in recently diagnosed diabetic patients. The authors emphasize the constant finding observed in the trials with some efficacy on preservation of β-cell function (anti-CD3, anti–B cells, and CTLA-4 Ig), i.e., a biphasic evolution of C-peptide secretion. There was an early significant improvement of C-peptide secretion noted at 6 months in comparison with that in control subjects, but thereafter …